Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Influence of repeated subcutaneous G-CSF injections on selected blood parameters relevant for monitoring programmes in sports drug testing.

Walpurgis K, Slijepcevic M, Wenzel F, Thomas A, Geyer H, Franz S, Schänzer W, Thevis M.

Drug Test Anal. 2012 Oct;4(10):798-802. doi: 10.1002/dta.1432. Epub 2012 Oct 9.

PMID:
23047806
2.

Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine.

Miles SA, Mitsuyasu RT, Moreno J, Baldwin G, Alton NK, Souza L, Glaspy JA.

Blood. 1991 May 15;77(10):2109-17.

3.

Hematological indices of erythropoietin administration in athletes.

Casoni I, Ricci G, Ballarin E, Borsetto C, Grazzi G, Guglielmini C, Manfredini F, Mazzoni G, Patracchini M, De Paoli Vitali E, et al.

Int J Sports Med. 1993 Aug;14(6):307-11.

PMID:
7691771
4.

Hematologic passport for athletes competing in endurance sports: a feasibility study.

Malcovati L, Pascutto C, Cazzola M.

Haematologica. 2003 May;88(5):570-81.

6.
7.

Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial.

Vannucchi AM, Bosi A, Ieri A, Guidi S, Saccardi R, Lombardini L, Linari S, Laszlo D, Longo G, Rossi-Ferrini P.

Bone Marrow Transplant. 1996 Apr;17(4):527-31.

PMID:
8722349
9.

Blood doping and its detection.

Jelkmann W, Lundby C.

Blood. 2011 Sep 1;118(9):2395-404. doi: 10.1182/blood-2011-02-303271. Epub 2011 Jun 7. Review.

10.
11.

Erythropoietin.

Jelkmann W.

Front Horm Res. 2016;47:115-27. doi: 10.1159/000445174. Epub 2016 Jun 27. Review.

PMID:
27348128
13.

Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietin in combination with granulocyte colony-stimulating factor: a multicenter randomized controlled study. Multicenter Study Group.

Bessho M, Hirashima K, Asano S, Ikeda Y, Ogawa N, Tomonaga M, Toyama K, Nakahata T, Nomura T, Mizoguchi H, Yoshida Y, Niitsu Y, Kohgo Y.

Eur J Haematol. 1997 Apr;58(4):265-72.

PMID:
9186538
14.
15.

Predicting erythroid response to recombinant erythropoietin plus granulocyte colony-stimulating factor therapy following a single subcutaneous bolus in patients with myelodysplasia.

Bowen D, Hyslop A, Keenan N, Groves M, Culligan D, Johnson P, Shaw A, Geddes F, Evans P, Porter J, Cavill I.

Haematologica. 2006 May;91(5):709-10.

16.

Synergy of growth factors during mobilization of peripheral blood precursor cells with recombinant human Flt3-ligand and granulocyte colony-stimulating factor in rabbits.

Pless M, Wodnar-Filipowicz A, John L, Baldomero H, Lyman SD, Nissen C, Gratwohl A.

Exp Hematol. 1999 Jan;27(1):155-61.

PMID:
9923454
17.

[Combination therapy with granulocyte colony-stimulating factor (G-CSF) and erythropoietin (EPO) induced prominent granulocyte increase in an elderly case of myelodysplastic syndrome (MDS)].

Jimbo T, Murata N, Tamura J, Sawamura M, Narahara N, Murakami H, Kubota K, Tsuchiya J, Naruse T.

Nihon Ronen Igakkai Zasshi. 1993 Mar;30(3):212-5. Japanese.

18.

The influence of the tourniquet time on hematological testing for antidoping purposes.

Lippi G, Salvagno GL, Solero GP, Guidi GC.

Int J Sports Med. 2006 May;27(5):359-62.

PMID:
16729374
19.

Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.

Musto P, Sanpaolo G, D'Arena G, Scalzulli PR, Matera R, Falcone A, Bodenizza C, Perla G, Carotenuto M.

Haematologica. 2001 Jan;86(1):44-51.

Supplemental Content

Support Center